Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the half-year period ended December 31, 2021. The report was lodged with the Australian Securities Exchange (ASX) on February 23, 2022, and furnished to the SEC as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific financial data. Revenue, profit, cash flow, margins, debt, and liquidity figures are not present in this excerpt.
Material Changes
No material changes or comparative financial data are disclosed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are contained within the referenced Exhibit 99.1 (ASX Half-Year Information), which is not included in the input.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 (ASX Half-Year Information) for actual financial statements and operational updates.
- Confirm the reporting period is the half-year ended December 31, 2021.
- Note that the filing date with the SEC was February 23, 2022.